OTCMKTS:ARGSQ Argos Therapeutics (ARGSQ) Stock Price, News & Analysis $0.05 0.00 (0.00%) As of 10/10/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argos Therapeutics Stock (OTCMKTS:ARGSQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Argos Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0552-Week Range$0.02▼$0.25VolumeN/AAverage Volume13,394 shsMarket Capitalization$571.70 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware. Read More Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARGSQ Stock News HeadlinesUnited Therapeutics price target raised to $400 from $360 at ArgusNovember 1, 2024 | markets.businessinsider.comBest Argos sale discounts, from garden furniture sets to BBQsMay 3, 2024 | uk.style.yahoo.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)ARGSQ Historical DataSeptember 27, 2023 | investing.comSeven Argos stores to shut NEXT month amid plans to close 100 for good by 2024July 29, 2023 | mirror.co.ukMArgos launches massive half price garden furniture sale as the heatwave continuesJune 22, 2023 | mirror.co.ukM2023-2029 mRNA Vaccines & Therapeutics Market Opportunities and ForecastApril 9, 2023 | marketwatch.commRNA Vaccines & Therapeutics Market Share and Forecast till 2031April 6, 2023 | marketwatch.comSee More Headlines ARGSQ Stock Analysis - Frequently Asked Questions How have ARGSQ shares performed this year? Argos Therapeutics' stock was trading at $0.0540 at the start of the year. Since then, ARGSQ shares have increased by 0.0% and is now trading at $0.0540. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc (OTCMKTS:ARGSQ) posted its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million. When did Argos Therapeutics' stock split? Argos Therapeutics shares reverse split before market open on Friday, January 19th 2018.The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Argos Therapeutics? Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/09/2017Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ARGSQ CIK1105533 Webwww.argostherapeutics.com Phone919-287-6300FaxN/AEmployees122Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.90 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.03Miscellaneous Outstanding Shares10,587,000Free FloatN/AMarket Cap$571.70 thousand OptionableNot Optionable Beta2.47 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:ARGSQ) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Argos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.